Trexquant Investment LP increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 130.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 35,501 shares of the company's stock after purchasing an additional 20,103 shares during the quarter. Trexquant Investment LP owned approximately 0.11% of Medpace worth $11,794,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of Medpace by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company's stock worth $854,087,000 after buying an additional 25,704 shares in the last quarter. State Street Corp grew its stake in Medpace by 7.2% during the 3rd quarter. State Street Corp now owns 752,957 shares of the company's stock valued at $251,337,000 after acquiring an additional 50,312 shares in the last quarter. Geode Capital Management LLC grew its stake in Medpace by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 656,130 shares of the company's stock valued at $218,031,000 after acquiring an additional 28,076 shares in the last quarter. Wellington Management Group LLP raised its holdings in Medpace by 36.0% in the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company's stock valued at $138,612,000 after acquiring an additional 109,886 shares during the last quarter. Finally, GW&K Investment Management LLC lifted its stake in Medpace by 93.9% in the 4th quarter. GW&K Investment Management LLC now owns 275,460 shares of the company's stock worth $91,516,000 after purchasing an additional 133,379 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
MEDP has been the subject of a number of analyst reports. Robert W. Baird upped their price target on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Leerink Partnrs raised Medpace to a "hold" rating in a research note on Monday, March 24th. Finally, Leerink Partners assumed coverage on shares of Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price target on the stock. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $376.30.
Get Our Latest Stock Analysis on MEDP
Medpace Trading Down 0.5 %
Shares of NASDAQ MEDP traded down $1.43 during mid-day trading on Monday, reaching $285.69. The company had a trading volume of 379,909 shares, compared to its average volume of 308,185. Medpace Holdings, Inc. has a 52-week low of $274.67 and a 52-week high of $459.77. The stock has a market cap of $8.70 billion, a P/E ratio of 22.36, a PEG ratio of 3.81 and a beta of 1.45. The firm has a 50 day simple moving average of $331.56 and a two-hundred day simple moving average of $337.32.
Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.
Medpace Profile
(
Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Featured Articles
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
